LEARNING OBJECTIVES

• Understanding the Current Epidemiology & Environment in mCRC
• Learning about new emerging treatments in mCRC, including the role of immunotherapy
• Managing toxicities and sequence agents in mCRC
• Assessing Clinical case studies in 3L mCRC

MICHAEL MORSE, MD, FACP, MHS

Professor of Medicine
Professor in the Department of Surgery
Member of the Duke Cancer Institute

“What’s new- Metastatic Colorectal Cancer”

WEDNESDAY, DECEMBER 12, 2018

JEWISH GENERAL HOSPITAL
12:00 - 13:00
Room E-711

NOUVEAU CHUM
17:00 - 18:00
Room D.S4.5030
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

THURSDAY, DECEMBER 13, 2018

MUHC- GLEN
08:00 - 09:00
Block D, Room D.02.4250

SACRE COEUR HOSPITAL
12:00 - 13:00
Room J-1125

FRIDAY, DECEMBER 14, 2018

HOPITAL CHARLES LEMOYNE
09:00 - 10:00
Room HN - 106

Refreshments will be served at each location.
To organize a videconference:
vspo@mcgill.ca

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics, Servier, Shire, Taiho Pharma, Teva Canada Innovation